首页 > 最新文献

Liver International最新文献

英文 中文
The Role of Endoscopic Ultrasound in Assessing Portal Hypertension: A State-of-the-Art Literature Review and Evolving Perspectives. 内窥镜超声在评估门脉高压中的作用:最新文献综述与不断发展的观点。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-04-01 Epub Date: 2024-11-27 DOI: 10.1111/liv.16176
Fabrizio Termite, Federica Borrelli de Andreis, Antonio Liguori, Antonio Gasbarrini, Fabia Attili, Cristiano Spada, Luca Miele

Background: Portal hypertension (PH) is a critical complication in patients with hepatic diseases. Its accurate evaluation is essential for early diagnosis, risk stratification, and management. Endoscopic ultrasound (EUS) has emerged as a promising diagnostic tool, offering high-resolution imaging of the portal venous system, hepatic vasculature, and surrounding structures.

Aims: This review aims at providing an overview of the evolving role of EUS in PH evaluation in patients with liver disease.

Materials and methods: A systematic search was conducted in PubMed and Google Scholar until 31 May 2024. Relevant studies were identified using keywords related to EUS and PH. Additional references were included based on expert knowledge and citation analysis. Only full-length papers and abstracts in English were considered.

Results: EUS demonstrates significant utility in PH assessment, offering high-resolution imaging and advanced tools like contrast enhancement (CE) and shear-wave elastography (SWE) for evaluating liver stiffness and correlating it with PH severity. EUS-guided portal pressure gradient (PPG) measurement provides a less invasive method for evaluating PH, potentially offering a safer alternative to conventional techniques.

Discussion: EUS offers unique advantages in PH assessment, enabling comprehensive evaluation in a single session. Despite its potential, limitations such as invasiveness, sedation-related variability, and restricted availability persist. Emerging techniques require further validation in larger cohorts and standardised training.

Conclusion: EUS is a valuable diagnostic tool for PH evaluation, with the potential to improve outcomes through earlier diagnosis and better stratification. Addressing its limitations through further research and standardised protocols is critical to optimize its clinical utility.

Trial registration: NCT04115046, NCT05728697, NCT05097963 and NCT03155282.

背景:门静脉高压症(PH)是肝病患者的一个重要并发症。对其进行准确评估对于早期诊断、风险分层和管理至关重要。目的:本综述旨在概述 EUS 在肝病患者门静脉高压评估中不断发展的作用:截至 2024 年 5 月 31 日,在 PubMed 和 Google Scholar 上进行了系统检索。使用与 EUS 和 PH 相关的关键词确定了相关研究。根据专家知识和引文分析纳入其他参考文献。仅考虑英文全文和摘要:EUS 在 PH 评估中具有重要作用,它提供了高分辨率成像以及造影剂增强(CE)和剪切波弹性成像(SWE)等先进工具,用于评估肝脏硬度并将其与 PH 的严重程度相关联。EUS 引导下的门静脉压力梯度(PPG)测量为 PH 评估提供了一种创伤较小的方法,有可能成为传统技术更安全的替代方法:讨论:EUS 在 PH 评估方面具有独特的优势,可在一次治疗中进行全面评估。尽管其潜力巨大,但仍存在一些局限性,如侵入性、镇静相关变异性和可用性受限。新出现的技术需要在更大的群体和标准化培训中得到进一步验证:EUS 是 PH 评估的重要诊断工具,有可能通过更早的诊断和更好的分层来改善预后。通过进一步研究和标准化方案解决其局限性对于优化其临床实用性至关重要:试验注册:NCT04115046、NCT05728697、NCT05097963和NCT03155282。
{"title":"The Role of Endoscopic Ultrasound in Assessing Portal Hypertension: A State-of-the-Art Literature Review and Evolving Perspectives.","authors":"Fabrizio Termite, Federica Borrelli de Andreis, Antonio Liguori, Antonio Gasbarrini, Fabia Attili, Cristiano Spada, Luca Miele","doi":"10.1111/liv.16176","DOIUrl":"10.1111/liv.16176","url":null,"abstract":"<p><strong>Background: </strong>Portal hypertension (PH) is a critical complication in patients with hepatic diseases. Its accurate evaluation is essential for early diagnosis, risk stratification, and management. Endoscopic ultrasound (EUS) has emerged as a promising diagnostic tool, offering high-resolution imaging of the portal venous system, hepatic vasculature, and surrounding structures.</p><p><strong>Aims: </strong>This review aims at providing an overview of the evolving role of EUS in PH evaluation in patients with liver disease.</p><p><strong>Materials and methods: </strong>A systematic search was conducted in PubMed and Google Scholar until 31 May 2024. Relevant studies were identified using keywords related to EUS and PH. Additional references were included based on expert knowledge and citation analysis. Only full-length papers and abstracts in English were considered.</p><p><strong>Results: </strong>EUS demonstrates significant utility in PH assessment, offering high-resolution imaging and advanced tools like contrast enhancement (CE) and shear-wave elastography (SWE) for evaluating liver stiffness and correlating it with PH severity. EUS-guided portal pressure gradient (PPG) measurement provides a less invasive method for evaluating PH, potentially offering a safer alternative to conventional techniques.</p><p><strong>Discussion: </strong>EUS offers unique advantages in PH assessment, enabling comprehensive evaluation in a single session. Despite its potential, limitations such as invasiveness, sedation-related variability, and restricted availability persist. Emerging techniques require further validation in larger cohorts and standardised training.</p><p><strong>Conclusion: </strong>EUS is a valuable diagnostic tool for PH evaluation, with the potential to improve outcomes through earlier diagnosis and better stratification. Addressing its limitations through further research and standardised protocols is critical to optimize its clinical utility.</p><p><strong>Trial registration: </strong>NCT04115046, NCT05728697, NCT05097963 and NCT03155282.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":"e16176"},"PeriodicalIF":6.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Technical Considerations on Sex Matching in Liver Transplantation for Hepatocellular Carcinoma
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-19 DOI: 10.1111/liv.16221
Chenxi Wang, Jin Shang, Huichuan Tian
{"title":"Technical Considerations on Sex Matching in Liver Transplantation for Hepatocellular Carcinoma","authors":"Chenxi Wang,&nbsp;Jin Shang,&nbsp;Huichuan Tian","doi":"10.1111/liv.16221","DOIUrl":"https://doi.org/10.1111/liv.16221","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Liver-Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-19 DOI: 10.1111/liv.70062
Marcel Razpotnik, Simona Bota, Philipp Wimmer, Peter Hofer, Michael Hackl, Matthias Fürstner, Hannes Alber, Raphael Mohr, Alexander Wree, Nirbaanjot Walia, Cornelius Engelmann, Münevver Demir, Frank Tacke, Markus Peck-Radosavljevic

Aim

Cirrhotic cardiomyopathy is characterised by myocardial dysfunction in patients with cirrhosis in the absence of other cardiac conditions. We aimed to develop and validate a scoring system to identify patients at high risk for reduced global longitudinal strain, a newly proposed marker of myocardial dysfunction in the updated diagnostic criteria for cirrhotic cardiomyopathy.

Methods

Prospectively recruited patients with cirrhosis in the training and validation groups underwent identical hepatological and cardiological evaluations, including strain echocardiography. Risk factors for myocardial dysfunction were identified using logistic regression.

Results

In a cohort of 452 consecutive patients, 278 were excluded due to non-cirrhotic cardiomyopathy or conditions potentially affecting strain measurements. The prevalence of reduced global longitudinal strain was 9.8% (13/133) in the training group and 19.5% (8/41) in the validation group. Multivariate logistic regression revealed BMI ≥ 28 kg/m2 (OR 7.02), CAP > 260 dB/m (OR 8.53), and age > 57 years (OR 4.68) as independent predictors of reduced myocardial contractility. These variables were combined and weighted based on their beta coefficients to develop the Liver-heart score (CAP > 260 dB/m [2 pts], BMI ≥ 28 kg/m2 [2 pts], age > 57 years [1 pt]). The AUC-ROC was 0.84 in the training and 0.83 in the validation cohort. A Liver-heart score of 5 points was associated with increased mortality, observed at 2 years (44.4% vs. 17.3%) and the end of the follow-up period (66.7% vs. 37.7%, HR 1.3, p < 0.01).

Conclusion

The Liver-heart score can accurately rule out reduced myocardial contractility and may be useful for risk stratification in cirrhotic patients.

{"title":"Development of Liver-Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging","authors":"Marcel Razpotnik,&nbsp;Simona Bota,&nbsp;Philipp Wimmer,&nbsp;Peter Hofer,&nbsp;Michael Hackl,&nbsp;Matthias Fürstner,&nbsp;Hannes Alber,&nbsp;Raphael Mohr,&nbsp;Alexander Wree,&nbsp;Nirbaanjot Walia,&nbsp;Cornelius Engelmann,&nbsp;Münevver Demir,&nbsp;Frank Tacke,&nbsp;Markus Peck-Radosavljevic","doi":"10.1111/liv.70062","DOIUrl":"https://doi.org/10.1111/liv.70062","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Cirrhotic cardiomyopathy is characterised by myocardial dysfunction in patients with cirrhosis in the absence of other cardiac conditions. We aimed to develop and validate a scoring system to identify patients at high risk for reduced global longitudinal strain, a newly proposed marker of myocardial dysfunction in the updated diagnostic criteria for cirrhotic cardiomyopathy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Prospectively recruited patients with cirrhosis in the training and validation groups underwent identical hepatological and cardiological evaluations, including strain echocardiography. Risk factors for myocardial dysfunction were identified using logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In a cohort of 452 consecutive patients, 278 were excluded due to non-cirrhotic cardiomyopathy or conditions potentially affecting strain measurements. The prevalence of reduced global longitudinal strain was 9.8% (13/133) in the training group and 19.5% (8/41) in the validation group. Multivariate logistic regression revealed BMI ≥ 28 kg/m<sup>2</sup> (OR 7.02), CAP &gt; 260 dB/m (OR 8.53), and age &gt; 57 years (OR 4.68) as independent predictors of reduced myocardial contractility. These variables were combined and weighted based on their beta coefficients to develop the Liver-heart score (CAP &gt; 260 dB/m [2 pts], BMI ≥ 28 kg/m<sup>2</sup> [2 pts], age &gt; 57 years [1 pt]). The AUC-ROC was 0.84 in the training and 0.83 in the validation cohort. A Liver-heart score of 5 points was associated with increased mortality, observed at 2 years (44.4% vs. 17.3%) and the end of the follow-up period (66.7% vs. 37.7%, HR 1.3, <i>p</i> &lt; 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The Liver-heart score can accurately rule out reduced myocardial contractility and may be useful for risk stratification in cirrhotic patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Clinically Significant Portal Hypertension in cACLD Individuals With Spleen Stiffness Measurement
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-19 DOI: 10.1111/liv.16241
Xiaofeng Zhang, Ling Zhou, Weihao Liang, Xiao Cheng, Qinjun He, Hui Li, Wenfan Luo, Jing Huang, Junying Li, Weibin Wang, Minghan Tu, Haiyu Wang, Pengcheng Ou, Biao Wen, Lushan Xiao, Damei Zhou, Vincent Wai-Sun Wong, Jinjun Chen

Background and Aims

The Baveno VII consensus recommends spleen stiffness measurement (SSM) for the detection of clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD). We aimed to evaluate the performance of SSM-based algorithms.

Methods

Consecutive cACLD individuals who underwent hepatic venous pressure gradient measurement, liver stiffness measurement (LSM), and SSM measured with the dedicated 100-Hz probe by vibration-controlled transient elastography were prospectively enrolled.

Results

From July 2021 to August 2024, a total of 395 patients were screened, and 185 cACLD cases were enrolled, of which 101 patients had CSPH. An SSM > 50 kPa demonstrated a positive predictive value (PPV) of 98.0% and a specificity of 98.8% for ruling in CSPH, correctly identifying 47.5% (48/101) of CSPH cases. Sensitivity analysis revealed that in 60 patients with aetiology removal or suppression, SSM > 50 kPa achieved both a PPV and specificity of 100%. Among the 125 patients with ongoing aetiologies, the PPV and specificity were 96.4% and 98.3%, respectively. Across HBV (with or without viral suppression) and non-HBV subgroups, the PPV and specificity consistently exceeded 90%. In decision curve analysis, SSM > 50 kPa provided the highest net benefit compared with other elastography-based algorithms when threshold probabilities exceeded 0.8.

Conclusions

We prospectively validated that SSM > 50 kPa, measured using the spleen-dedicated probe, is sufficient for identifying CSPH in individuals with cACLD.

Trial Registration

NCT04820166

{"title":"Identification of Clinically Significant Portal Hypertension in cACLD Individuals With Spleen Stiffness Measurement","authors":"Xiaofeng Zhang,&nbsp;Ling Zhou,&nbsp;Weihao Liang,&nbsp;Xiao Cheng,&nbsp;Qinjun He,&nbsp;Hui Li,&nbsp;Wenfan Luo,&nbsp;Jing Huang,&nbsp;Junying Li,&nbsp;Weibin Wang,&nbsp;Minghan Tu,&nbsp;Haiyu Wang,&nbsp;Pengcheng Ou,&nbsp;Biao Wen,&nbsp;Lushan Xiao,&nbsp;Damei Zhou,&nbsp;Vincent Wai-Sun Wong,&nbsp;Jinjun Chen","doi":"10.1111/liv.16241","DOIUrl":"https://doi.org/10.1111/liv.16241","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>The Baveno VII consensus recommends spleen stiffness measurement (SSM) for the detection of clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD). We aimed to evaluate the performance of SSM-based algorithms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Consecutive cACLD individuals who underwent hepatic venous pressure gradient measurement, liver stiffness measurement (LSM), and SSM measured with the dedicated 100-Hz probe by vibration-controlled transient elastography were prospectively enrolled.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From July 2021 to August 2024, a total of 395 patients were screened, and 185 cACLD cases were enrolled, of which 101 patients had CSPH. An SSM &gt; 50 kPa demonstrated a positive predictive value (PPV) of 98.0% and a specificity of 98.8% for ruling in CSPH, correctly identifying 47.5% (48/101) of CSPH cases. Sensitivity analysis revealed that in 60 patients with aetiology removal or suppression, SSM &gt; 50 kPa achieved both a PPV and specificity of 100%. Among the 125 patients with ongoing aetiologies, the PPV and specificity were 96.4% and 98.3%, respectively. Across HBV (with or without viral suppression) and non-HBV subgroups, the PPV and specificity consistently exceeded 90%. In decision curve analysis, SSM &gt; 50 kPa provided the highest net benefit compared with other elastography-based algorithms when threshold probabilities exceeded 0.8.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We prospectively validated that SSM &gt; 50 kPa, measured using the spleen-dedicated probe, is sufficient for identifying CSPH in individuals with cACLD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>NCT04820166</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Commentary on ‘Steatotic Liver Disease in Younger Adults Is Associated With Altered Gut Microbiology’
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-19 DOI: 10.1111/liv.70070
Liying Guan, Ying Zhu, Juntao Wang
{"title":"A Commentary on ‘Steatotic Liver Disease in Younger Adults Is Associated With Altered Gut Microbiology’","authors":"Liying Guan,&nbsp;Ying Zhu,&nbsp;Juntao Wang","doi":"10.1111/liv.70070","DOIUrl":"https://doi.org/10.1111/liv.70070","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protection of Novel Adenovirus Vectored Vaccine in Rats Against Wild-Type Hepacivirus and Variant Infections
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-17 DOI: 10.1111/liv.70045
Shengxue Luo, Qitao Deng, Chaolan Liang, Panli Zhang, Peng Zou, Shikai Deng, Meng Zhang, Feifeng Zeng, Ling Zhang, Yongshui Fu, Chengyao Li, Tingting Li

Background and Aims

Hepatitis C virus (HCV) vaccines are urgently needed to achieve WHO's goal for the elimination of viral hepatitis by 2030. The lack of suitable animal models for evaluating vaccine efficacy has greatly hindered the development of HCV vaccines. By using the rat model chronically infected with rodent hepacivirus from Rattus norvegicus (RHV-rn1), a hepacivirus homologously close to HCV as a surrogate model of HCV infection, we assessed the protective effectiveness of the RHV-rn1 vaccine Sad23L-RHVns.

Methods

Sad23L-RHVns vaccine was constructed with the nonstructural proteins (NS) 3–5B genes of RHV-rn1. SD rats were immunised with Sad23L-RHVns by prime or prime-boost regimen via intramuscular injection, then challenged 4 weeks post vaccination by RHV-rn1. A part of the rats were rechallenged with a variant 15 weeks post the first challenge of RHV-rn1.

Results

The specific T-cell responses to NS3-5B antigens were induced by prime immunisation, which were significantly enhanced by boost vaccination. The inoculated rats and controls were challenged by wild-type RHV-rn1, of all the primed and control rats having persistently high levels of viremia, whereas 7 of 9 (77.8%) boosted rats cleared RHV-rn1 infection. Interestingly, the resolver acquired immune protection against re-challenging with variant and showed significantly higher T-cell responses than the nonresolver in 25 weeks post rechallenge.

Conclusions

Sad23L-RHVns with prime-boost regimen protected 77.8% of rats against wild-type RHV-rn1 infection, and resolvers showed high levels and maintenance of T cell immunity against the variant. Our findings that maintenance of effective T cell immunity is required for RHV-rn1 resolution may provide insight to develop the HCV vaccine in humans.

{"title":"Protection of Novel Adenovirus Vectored Vaccine in Rats Against Wild-Type Hepacivirus and Variant Infections","authors":"Shengxue Luo,&nbsp;Qitao Deng,&nbsp;Chaolan Liang,&nbsp;Panli Zhang,&nbsp;Peng Zou,&nbsp;Shikai Deng,&nbsp;Meng Zhang,&nbsp;Feifeng Zeng,&nbsp;Ling Zhang,&nbsp;Yongshui Fu,&nbsp;Chengyao Li,&nbsp;Tingting Li","doi":"10.1111/liv.70045","DOIUrl":"https://doi.org/10.1111/liv.70045","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Hepatitis C virus (HCV) vaccines are urgently needed to achieve WHO's goal for the elimination of viral hepatitis by 2030. The lack of suitable animal models for evaluating vaccine efficacy has greatly hindered the development of HCV vaccines. By using the rat model chronically infected with rodent hepacivirus from <i>Rattus norvegicus</i> (RHV-rn1), a hepacivirus homologously close to HCV as a surrogate model of HCV infection, we assessed the protective effectiveness of the RHV-rn1 vaccine Sad23L-RHVns.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Sad23L-RHVns vaccine was constructed with the nonstructural proteins (NS) 3–5B genes of RHV-rn1. SD rats were immunised with Sad23L-RHVns by prime or prime-boost regimen via intramuscular injection, then challenged 4 weeks post vaccination by RHV-rn1. A part of the rats were rechallenged with a variant 15 weeks post the first challenge of RHV-rn1.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The specific T-cell responses to NS3-5B antigens were induced by prime immunisation, which were significantly enhanced by boost vaccination. The inoculated rats and controls were challenged by wild-type RHV-rn1, of all the primed and control rats having persistently high levels of viremia, whereas 7 of 9 (77.8%) boosted rats cleared RHV-rn1 infection. Interestingly, the resolver acquired immune protection against re-challenging with variant and showed significantly higher T-cell responses than the nonresolver in 25 weeks post rechallenge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Sad23L-RHVns with prime-boost regimen protected 77.8% of rats against wild-type RHV-rn1 infection, and resolvers showed high levels and maintenance of T cell immunity against the variant. Our findings that maintenance of effective T cell immunity is required for RHV-rn1 resolution may provide insight to develop the HCV vaccine in humans.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Case Supporting Drug-Induced Autoimmune Hepatitis: Updated Insights and Analysis of the FAERS Data
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-16 DOI: 10.1111/liv.70055
Duoqin Huang, Jianglong Shi
{"title":"Real-World Case Supporting Drug-Induced Autoimmune Hepatitis: Updated Insights and Analysis of the FAERS Data","authors":"Duoqin Huang,&nbsp;Jianglong Shi","doi":"10.1111/liv.70055","DOIUrl":"https://doi.org/10.1111/liv.70055","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behaviour-Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B (ANRS CO22 HEPATHER)
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-15 DOI: 10.1111/liv.70065
Clémence Ramier, Camelia Protopopescu, Vincent Di Beo, Lucia Parlati, Fabienne Marcellin, Fabrice Carrat, Tarik Asselah, Marc Bourlière, Patrizia Carrieri, the ANRS/AFEF CO22 HEPATHER Study Group

Background and Aims

Early assessment of hepatocellular carcinoma (HCC) risk could improve long-term outcomes in people with chronic hepatitis B virus (HBV) infection. Some existing HCC predictive scores are not easily implementable. We developed easy-to-use HCC predictive scores based on behavioural and routine bio-clinical data in people with chronic HBV infection.

Methods

Eight-year follow-up data was analysed from people with chronic HBV infection enrolled in the French ANRS CO22 HEPATHER cohort. Patients were randomly split into two samples (training/testing). A multivariable Cox model for time to HCC was estimated on the training sample. The HCC predictive score was computed by summing the points assigned to model predictors, normalising their coefficients over a 10-year age increment, and rounding to the nearest integer. The Youden index identified the score's optimal risk threshold. Comparisons with existing predictive scores were performed on the testing sample.

Results

In the study population (N = 4370; 63% of men; 65% of < 50 years old), 56 HCC cases occurred during 25,900 follow-up person-years. Two HCC predictive scores were defined: SADAPTT (daily soft drink consumption, age, hepatitis Delta infection, unhealthy alcohol use, platelet count, heavy tobacco smoking, and HBV treatment) and ADAPTT (the same predictors except for daily soft drink consumption), with ranges 0–13 and 0–14, respectively, and values ≥ 3 indicating a high HCC risk. Their performances were similar to existing scores.

Conclusions

We developed two effective behaviour-based HCC predictive scores, implementable in many settings, including primary care and decentralised areas. Further studies are needed to validate these scores in other datasets.

{"title":"Behaviour-Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B (ANRS CO22 HEPATHER)","authors":"Clémence Ramier,&nbsp;Camelia Protopopescu,&nbsp;Vincent Di Beo,&nbsp;Lucia Parlati,&nbsp;Fabienne Marcellin,&nbsp;Fabrice Carrat,&nbsp;Tarik Asselah,&nbsp;Marc Bourlière,&nbsp;Patrizia Carrieri,&nbsp;the ANRS/AFEF CO22 HEPATHER Study Group","doi":"10.1111/liv.70065","DOIUrl":"https://doi.org/10.1111/liv.70065","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Early assessment of hepatocellular carcinoma (HCC) risk could improve long-term outcomes in people with chronic hepatitis B virus (HBV) infection. Some existing HCC predictive scores are not easily implementable. We developed easy-to-use HCC predictive scores based on behavioural and routine bio-clinical data in people with chronic HBV infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eight-year follow-up data was analysed from people with chronic HBV infection enrolled in the French ANRS CO22 HEPATHER cohort. Patients were randomly split into two samples (training/testing). A multivariable Cox model for time to HCC was estimated on the training sample. The HCC predictive score was computed by summing the points assigned to model predictors, normalising their coefficients over a 10-year age increment, and rounding to the nearest integer. The Youden index identified the score's optimal risk threshold. Comparisons with existing predictive scores were performed on the testing sample.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the study population (<i>N</i> = 4370; 63% of men; 65% of &lt; 50 years old), 56 HCC cases occurred during 25,900 follow-up person-years. Two HCC predictive scores were defined: SADAPTT (daily soft drink consumption, age, hepatitis Delta infection, unhealthy alcohol use, platelet count, heavy tobacco smoking, and HBV treatment) and ADAPTT (the same predictors except for daily soft drink consumption), with ranges 0–13 and 0–14, respectively, and values ≥ 3 indicating a high HCC risk. Their performances were similar to existing scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We developed two effective behaviour-based HCC predictive scores, implementable in many settings, including primary care and decentralised areas. Further studies are needed to validate these scores in other datasets.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking Methotrexate Hepatotoxicity: A Closer Look at Intrathecal Risks and Genetic Susceptibility
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-15 DOI: 10.1111/liv.70069
Muhammad Khubaib Iftikhar
{"title":"Rethinking Methotrexate Hepatotoxicity: A Closer Look at Intrathecal Risks and Genetic Susceptibility","authors":"Muhammad Khubaib Iftikhar","doi":"10.1111/liv.70069","DOIUrl":"https://doi.org/10.1111/liv.70069","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic Risk Factors for Steatotic Liver Disease After Liver Transplantation
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-03-15 DOI: 10.1111/liv.70067
Ville Liukkonen, Maria Semenova, Kati Hyvärinen, Jouni Lauronen, Jukka Partanen, Johanna Arola, Arno Nordin, Martti Färkkilä, Fredrik Åberg

Background

The role of genetic risk factors for steatotic liver disease (SLD) is intriguing in liver transplantation (LT), as both donor and recipient genetic factors may play a role. There are only a few small-scale studies published so far.

Methods

We analysed the incidence and risk factors for post-LT SLD and the impact of 56 SLD-associated genetic variants in 595 donor-recipient pairs with liver biopsy available ≥ 6 months after LT. We evaluated whether the polygenic risk score (PRS-5) improves the ability to predict post-LT SLD in addition to non-genetic risk factors.

Results

SLD after LT was diagnosed in 34.5% of patients during a median 7.6-year follow-up. In multivariate analysis including non-genetic risk factors, donor PNPLA3 rs738409-G (HR for SLD: C/G 1.34, p = 0.051, G/G 2.25, p = 0.004), donor HSD17B13 rs72613567-TA (HR for SLD: TA/T 0.68, p = 0.02 TA/TA HR 0.50, p = 0.10) and recipient UCP2 rs695366-G (HR for SLD: A/G 0.63, p = 0.002, G/G HR 0.50, p = 0.04) appeared as the most important genetic risk factors for post-LT SLD. The addition of PRS-5 to a multivariate regression model (including non-genetic risk factors) improved the predictive ability for SLD only modestly (AUC 0.78 to 0.80).

Conclusions

Various genetic variants contribute to post-LT SLD with separate variants among recipients and donors, with donor PNPLA3 rs738409-G as the most significant risk allele. Still, donor and recipient genotyping provide only modest additional value for individual risk stratification over phenotype data, highlighting the role of modifiable risk factors.

背景脂肪性肝病(SLD)的遗传风险因素在肝脏移植(LT)中的作用令人好奇,因为供体和受体的遗传因素都可能起作用。迄今为止,仅有少数几项小规模研究发表。 方法 我们分析了肝移植后 SLD 的发病率和风险因素,以及 56 个与 SLD 相关的基因变异对 595 对肝移植后≥ 6 个月可进行肝活检的供体和受体的影响。我们评估了除非遗传性风险因素外,多基因风险评分(PRS-5)是否能提高预测LT后SLD的能力。 结果 在中位 7.6 年的随访中,34.5% 的患者在 LT 后被诊断出 SLD。在包括非遗传风险因素的多变量分析中,供体 PNPLA3 rs738409-G(SLD 的 HR:C/G 1.34,p = 0.051,G/G 2.25,p = 0.004)、供体 HSD17B13 rs72613567-TA(SLD 的 HR:TA/T 0.68,p = 0.02 TA/TA HR 0.50,p = 0.10)和受体 UCP2 rs695366-G(SLD 的 HR:A/G 0.63,p = 0.002,G/G HR 0.50,p = 0.04)似乎是 LT 后 SLD 最重要的遗传风险因素。将 PRS-5 加入多变量回归模型(包括非遗传风险因素)后,SLD 的预测能力仅略有提高(AUC 0.78 至 0.80)。 结论 各种遗传变异会导致 LT 后 SLD,受体和供体中存在不同的变异,供体 PNPLA3 rs738409-G 是最重要的风险等位基因。尽管如此,与表型数据相比,供体和受体基因分型在个体风险分层方面仅提供了适度的额外价值,突出了可改变的风险因素的作用。
{"title":"Genetic Risk Factors for Steatotic Liver Disease After Liver Transplantation","authors":"Ville Liukkonen,&nbsp;Maria Semenova,&nbsp;Kati Hyvärinen,&nbsp;Jouni Lauronen,&nbsp;Jukka Partanen,&nbsp;Johanna Arola,&nbsp;Arno Nordin,&nbsp;Martti Färkkilä,&nbsp;Fredrik Åberg","doi":"10.1111/liv.70067","DOIUrl":"https://doi.org/10.1111/liv.70067","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The role of genetic risk factors for steatotic liver disease (SLD) is intriguing in liver transplantation (LT), as both donor and recipient genetic factors may play a role. There are only a few small-scale studies published so far.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analysed the incidence and risk factors for post-LT SLD and the impact of 56 SLD-associated genetic variants in 595 donor-recipient pairs with liver biopsy available ≥ 6 months after LT. We evaluated whether the polygenic risk score (PRS-5) improves the ability to predict post-LT SLD in addition to non-genetic risk factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>SLD after LT was diagnosed in 34.5% of patients during a median 7.6-year follow-up. In multivariate analysis including non-genetic risk factors, donor PNPLA3 rs738409-G (HR for SLD: C/G 1.34, <i>p</i> = 0.051, G/G 2.25, <i>p</i> = 0.004), donor HSD17B13 rs72613567-TA (HR for SLD: TA/T 0.68, <i>p</i> = 0.02 TA/TA HR 0.50, <i>p</i> = 0.10) and recipient UCP2 rs695366-G (HR for SLD: A/G 0.63, <i>p</i> = 0.002, G/G HR 0.50, <i>p</i> = 0.04) appeared as the most important genetic risk factors for post-LT SLD. The addition of PRS-5 to a multivariate regression model (including non-genetic risk factors) improved the predictive ability for SLD only modestly (AUC 0.78 to 0.80).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Various genetic variants contribute to post-LT SLD with separate variants among recipients and donors, with donor PNPLA3 rs738409-G as the most significant risk allele. Still, donor and recipient genotyping provide only modest additional value for individual risk stratification over phenotype data, highlighting the role of modifiable risk factors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Liver International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1